Wynnewood, United States
ProstaGene is a biotechnology startup founded in 2010 in the United States. The company focuses on developing technology based on patents from the Founder, Dr. Richard G. Pestell. ProstaGene's core mission is to integrate proprietary molecular diagnostics with therapeutic screening to create novel treatments for cancer, particularly prostate cancer.
The company has made significant strides in its research and development, with the successful creation of a diagnostic test that demonstrates a predictive value of >98% in distinguishing between benign and malignant prostate cancer. Additionally, ProstaGene has developed a prognostic test that identifies a group of patients with poor outcomes based on gene expression in their prostate tumors. Furthermore, the company has established a novel platform for preclinical testing of therapies for metastatic prostate cancer in immune competent mice and has identified a highly effective therapeutic for metastatic prostate cancer through preclinical testing.
With its focus on biotechnology and health care industries, ProstaGene's innovative approach to cancer treatment holds promise for addressing unmet medical needs in the field. While the details of the company's last investment and investors remain undisclosed, ProstaGene's advancements in cancer diagnostics and therapeutic development position it as a noteworthy player in the biotechnology startup landscape.
